NASDAQ$OABI
OmniAb Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported a strong start to the year with revenue increase and advancement in partner programs.
OmniAb reported a strong start to 2023, with revenue increasing to $16.9 million due to a $10.0 million milestone payment. The company reached 301 active programs, with 27 in clinical development or approved for commercialization.
- Revenue for the first quarter of 2023 was $16.9 million, compared to $9.6 million for the same period in 2022.
- Net loss for the first quarter of 2023 was $6.1 million, or $0.06 per share, compared to a net loss of $6.3 million, or $0.08 per share, for the same period in 2022.
- As of March 31, 2023, OmniAb had cash, cash equivalents and short-term investments of $113.6 million.
- The company reached 301 active programs, with 27 in clinical development or approved for commercialization.
Headline financials
Revenue & EPS history
OmniAb · Revenue · Quarterly
$16.9M
Revenue by segment
OmniAb · $16.9M total across 3 segments · Q1 2023
- License and Milestone$12.6M+208.4%74.7%
- Service Revenue$3.96M-24.7%23.4%
- Royalty Revenue$315K+19.8%1.9%
Forward guidance
The Company expects its year-end 2023 cash, cash equivalents and short-term investments balance to be slightly higher than year-end 2022. Current cash, cash equivalents and short-term investments, along with the cash the Company generates from operations, are expected to be sufficient to fund operations for the foreseeable future.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q1 2023
-2.1%
Avg return
Earnings day
+1.5%
Avg return
5 days after
+4.1%
Avg return
30 days after
39%
7 / 18 earnings
Positive
+9.9%
Q4 2025
Best reaction
-20.4%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.1% | +29.4% | +72.7% | |
| Q4 2025 | +9.9% | +9.9% | -14.9% | |
| Q3 2025 | -4.1% | +0.7% | +31.8% | |
| Q1 2025 | -7.2% | -3.2% | -4.5% | |
| Q4 2024 | -20.4% | -20.4% | -43.9% | |
| Q3 2024 | -11.5% | -15.7% | -13.0% | |
| Q2 2024 | +4.4% | +4.9% | -2.2% | |
| Q1 2024 | +3.1% | -0.9% | +2.2% | |
| Q4 2023 | -2.5% | +0.8% | -11.4% | |
| Q3 2023 | -6.8% | +3.5% | +7.3% | |
| Q2 2023 | -5.7% | -3.8% | -10.4% | |
| Q1 2023 | +6.1% | +16.1% | +37.3% | |
| Q4 2022 | +9.5% | +10.1% | +3.6% | |
| Q3 2022 | -15.5% | -4.1% | +19.3% | |
| Q2 2022 | +0.2% | +0.1% | +0.3% | |
| Q1 2022 | -0.0% | +0.0% | +0.1% | |
| Q4 2021 | -0.0% | -0.1% | -0.1% | |
| Q3 2021 | +0.0% | +0.0% | -0.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro